Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Binding

Study Background and Research Question

The emergence of SARS-CoV-2, the causative agent of COVID-19, has intensified research into the molecular determinants of viral entry and host susceptibility. While the primary receptor facilitating SARS-CoV-2 entry is angiotensin-converting enzyme 2 (ACE2), recent work has identified alternative receptors, including neuropilin-1 (NRP1) and AXL, that can mediate infection—especially in tissues with low ACE2 expression (Oliveira et al., 2025). Alongside this, the renin–angiotensin–aldosterone system (RAAS) and its constituent peptides, such as Angiotensin II and its derivatives, are well established in cardiovascular regulation and pathophysiology. However, their direct effects on viral–host interactions remained largely unexplored. This study addresses whether naturally occurring angiotensin peptides—specifically those generated through physiological cleavage events—modulate the binding of the SARS-CoV-2 spike protein to its entry receptors.

Key Innovation from the Reference Study

The core innovation of Oliveira et al. (2025) lies in the systematic evaluation of how endogenous angiotensin peptides, including truncated forms such as Angiotensin III (Arg-Val-Tyr-Ile-His-Pro-Phe), influence the affinity between the SARS-CoV-2 spike protein and its cellular receptors. Notably, the study uncovers that specific N-terminally truncated peptides not only enhance spike–AXL binding but do so with greater potency than canonical Angiotensin II. This reframes RAAS peptides as potential modulators of viral entry, expanding their relevance beyond classical cardiovascular and renal biology (Oliveira et al., 2025).

Methods and Experimental Design Insights

The investigators employed antibody-based binding assays to quantify interactions between recombinant SARS-CoV-2 spike protein and host cell receptors (AXL, ACE2, NRP1) in the presence of various angiotensin peptides. Both full-length and truncated peptide analogs were evaluated, with attention to site-specific modifications such as tyrosine substitution and phosphorylation. The experimental approach enabled precise dissection of structure–activity relationships, highlighting how specific sequence truncations and modifications alter biological effects. Comparisons were made between peptides derived from both C-terminal and N-terminal cleavages of Angiotensin II, including Angiotensin III (2–8) and Angiotensin IV (3–8), as well as shorter analogs (Oliveira et al., 2025).

Protocol Parameters

• assay | antibody-based receptor–ligand binding | 1–10 μM peptide concentration | applicable to spike–AXL, spike–ACE2, spike–NRP1 binding measurements | enables quantification of peptide-dependent binding modulation | paper
• assay | N-terminal truncated peptide (e.g., Angiotensin III, Arg-Val-Tyr-Ile-His-Pro-Phe) | 2.7-fold maximum enhancement observed for Angiotensin IV | suitable for investigation of spike–AXL interactions | demonstrates greater activity than Angiotensin II | paper
• assay | substitution/phosphorylation at Tyr4 | increased spike–AXL binding observed | relevant for structure–activity relationship studies | implicates Tyr4 as a key modulator | paper
• assay | use of AT1/AT2 receptor ligands in parallel | context-dependent, for mechanistic dissection | recommended to parse receptor-specific effects | workflow_recommendation

Core Findings and Why They Matter

The study establishes that angiotensin peptides—especially those truncated at the N-terminus, such as Angiotensin III and Angiotensin IV—markedly enhance the binding of SARS-CoV-2 spike protein to AXL (Oliveira et al., 2025). Angiotensin II increased spike–AXL binding two-fold, while Angiotensin IV induced a 2.7-fold enhancement, surpassing the effects of Angiotensin II. C-terminal truncations (e.g., Angiotensin (1–7), (1–6)) retained activity similar to Angiotensin II, whereas N-terminal truncations resulted in even greater potentiation. Importantly, these effects appeared specific to AXL, as spike–ACE2 and spike–NRP1 binding were less consistently affected, though Angiotensin IV also modestly enhanced binding to these receptors. Structural modifications at tyrosine residues further augmented spike–AXL binding, implicating this residue as a critical determinant of peptide activity. Mechanistically, these findings suggest a direct biochemical interface between RAAS peptide dynamics and the molecular determinants of SARS-CoV-2 infectivity.

Comparison with Existing Internal Articles

Several internal resources provide context for the role of Angiotensin III in RAAS biology and experimental design:

• "Angiotensin III (human, mouse): Mechanistic Leverage…" frames Angiotensin III as a pivotal RAAS peptide, emphasizing its dual activity as a pressor activity mediator and aldosterone secretion inducer. This mechanistic perspective aligns with the reference paper's emphasis on receptor-level effects, though the internal resource focuses on cardiovascular and neuroendocrine axes rather than viral entry.
• "Angiotensin III (Arg-Val-Tyr-Ile-His-Pro-Phe): Strategic…" highlights the translational promise of Angiotensin III in infectious disease modeling, foreshadowing its relevance in contexts such as SARS-CoV-2. The reference study extends this by providing direct molecular evidence for such cross-domain activity.
• "Angiotensin III: Applied Protocols for Cardiovascular Research" and "Advanced Workflows for RAAS & Cardiovascular…" deliver practical guidance for using Angiotensin III in receptor signaling and pressor response assays, which can be adapted for studies probing viral receptor interactions.

In sum, while internal articles have established the versatility of Angiotensin III as a cardiovascular research peptide, the reference paper adds a new layer by directly connecting these peptides to viral pathogenesis via receptor modulation.

Limitations and Transferability

The principal limitation of the study is its reliance on in vitro binding assays, which, although informative, do not fully recapitulate the complexity of in vivo infection dynamics. The observed potentiation of spike–AXL binding by angiotensin peptides, including Angiotensin III, requires further validation in live cell and animal models to determine physiological relevance (Oliveira et al., 2025). Additionally, the functional consequences of enhanced spike–AXL binding—such as effects on viral infectivity, tropism, or disease severity—remain to be elucidated. The specificity of peptide effects for different receptor subtypes and the interplay with endogenous RAAS signaling in diverse tissues also warrant further investigation. Therefore, while the findings provide a compelling mechanistic link, their direct translational impact should be interpreted cautiously until confirmed in more complex biological systems.

Why this cross-domain matters, maturity, and limitations

The interface between cardiovascular peptides and viral entry mechanisms exemplifies a promising cross-domain research avenue, with potential implications for understanding susceptibility to infection in patients with dysregulated RAAS activity or those receiving RAAS-modulating therapies. However, the maturity of this bridge remains preliminary (Oliveira et al., 2025). The current evidence is limited to receptor–ligand binding dynamics; further studies are needed to clarify whether modulating Angiotensin III or related peptides can influence clinical outcomes in COVID-19 or other viral diseases.

Research Support Resources

To facilitate further research in this emerging area, well-characterized reagents are essential. Researchers can utilize Angiotensin III (human, mouse) (SKU A1043), a highly pure, sequence-defined peptide (Arg-Val-Tyr-Ile-His-Pro-Phe), to support advanced workflows in receptor binding studies, RAAS signaling assays, and cross-domain modeling of peptide-mediated viral entry (product_spec). For additional protocol guidance and mechanistic perspectives, see "Angiotensin III (Arg-Val-Tyr-Ile-His-Pro-Phe): Strategic…" and "Mechanistic Leverage…". Storage, solubility, and handling guidelines are detailed in product documentation to ensure reproducible experimental outcomes.